BioVie Inc.

The momentum for this stock is not very good. BioVie Inc. is not a good growth stock. BioVie Inc. is a mediocre stock to choose.

News

BioVie gets FDA okay for Phase 2 study for long COVID drug

Seeking Alpha - Healthcare BioVie gets FDA okay for Phase 2 study for long COVID drug...\n more…

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Globe Newswire Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID Key milestone reached...\n more…

BioVie to give data for epigenetic basis for bezisterim and aging at ARDD 2024

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Globe Newswire Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration...\n more…

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

Globe Newswire Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidenceCARSON CITY, Nev., Aug. 13...\n more…

BioVie says FDA aligns with mid-stage Parkinson's disease trial

Seeking Alpha - Healthcare BioVie says FDA aligns with mid-stage Parkinson's disease trial...\n more…